What makes you come to that conclusion? Is it just the SP "manipulation" or is it the confluence of factors - FDA guidance, 3 positive P2 trials, SP manipulation etc?
I know you have previously shared your views on valuations. Can I ask - do you think the depressed SP will have a significant impact on any TO price?
I know a DCF model is proposed but do you think the supressed SP is a means of trying to lower to DCF valuation?
Hope that makes sense!
What makes you come to that conclusion? Is it just the SP...
-
- There are more pages in this discussion • 1,392 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.03 |
Change
0.700(4.29%) |
Mkt cap ! $2.176B | |||
| Open | High | Low | Value | Volume |
| $16.49 | $17.21 | $16.44 | $11.40M | 677.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4624 | $17.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.05 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |